哨兵淋巴结程序（SN）是一种标准程序，已经证明对于T1/T2 cN0口腔鳞状细胞癌（OSCC）具有安全和有效性，针对于阳性的SN病人进行完成性颈淋巴结清扫（CND）。本研究的目的是描述SN阳性的OSCC组中淋巴结受累的特征。在2000年至2013年期间，对于T1/T2 cN0的SN阳性，并进行了CND的OSCC患者进行了这项单中心、前瞻性队列研究。301名患者中，54人至少有一个阳性SN。在43例中（80％），只有SN（S）受侵犯；36/54（67％）情况下仅有一个SN受侵犯。考虑到以下因素：SN微/宏转移，原发肿瘤的侵袭深度（DOI），周围神经转移，淋巴血管受累，原发肿瘤位置，T期和外部淋巴结扩展，未发现任何关于颈淋巴结清扫的淋巴结受累的预测因素。SN微转移的受累（n=22）与一个SN + CND-显着相关（p=0.017）。在仅在SN中出现微转移的患者中（n=20/54）单个微转移的受累时间较长（P=0.017）。80％的T1/T2 cN0 OSCC SN阳性患者在CND中没有其他淋巴结转移，这说明了这种程序的潜在益处。需要测试诸如SN转移大小等预测因素，以分层非SN淋巴结阳性风险，实现个体化治疗，降低治疗中的并发症，同时保证肿瘤学的安全性。版权所有©2023 Elsevier Ltd。保留所有权利。

Sentinel node procedure (SN) is a standard procedure that has shown its safety and effectiveness for T1/T2 cN0 oral squamous cell carcinoma (OSCC), with completion neck dissection (CND) for patients with positive SN. The aim of this study was to characterize the nodal involvement in a cohort of SN + OSCC.Patients with T1/T2 cN0 OSCC with positive SN with CND were included in this single-center, prospective cohort study between 2000 and 2013.54/301 patients had at least one positive SN. In 43/54 (80 %) cases, only the SN(s) were invaded; with only one SN involved (SN+=1) in 36/54 (67 %) cases. No predictive factors of nodal involvement in the CND were found considering the followings: SN micro/macrometastases, primary tumor's depth of invasion (DOI), perineural spread, lymphovascular involvement, primary tumor location, T stage and extranodal extension. The SN micrometastatic involvement (n = 22) was significantly associated with only one SN + CND- (p = 0.017). In the group of patients with unique micrometastatic involvement in the SN (n = 20/54), there was a higher isolated nodal recurrence free time (p = 0.017).80% of T1/T2 cN0 OSCC with positive SN had no other lymph node metastases in the CND, questioning the potential benefits of this procedure. Predictive factors such as the size of the SN metastasis need to be tested to stratify the risk of positive non-SN lymph nodes leading to a personalized treatment, lowering the therapeutic morbidity while maintaining the oncologic safety.Copyright © 2023 Elsevier Ltd. All rights reserved.